Contura Vet Opens US Workplace, Assuming Distribution of Arthramid®Vet, Synamid® and Mictamid® – The Horse
FRANKLIN, TN — October 19, 2021 – Contura Vet, the veterinary subsidiary of Contura Worldwide LTD, has introduced the opening of their first US primarily based workplace and has assumed all advertising and distribution actions to veterinarians for his or her three veterinary merchandise. Arthramid®Vet, Synamid® and Mictamid® belong to a household of patented polyacrylamide hydrogels (PAAG) for intra-articular and urethral injection, following a 20-year legacy of Contura Worldwide’s portfolio of PAAG’s for human use. Arthramid®Vet and Synamid® are the primary PAAG’s labeled for veterinary use within the USA for non-infectious causes of joint illness in horses and canine together with all levels of osteoarthritis (OA) and degenerative joint illness (DJD). Mictamid® is labeled for the administration of urinary incontinence. This portfolio of merchandise brings progressive options to veterinarians for the administration of circumstances with excessive incidence charges in practices.
Contura Vet’s PAAG merchandise have been used within the horse for 10 years world wide. The early adoption and security profile of Arthramid®Vet and Synamid® in horses and canine spotlight veterinarians want and luxury stage in transferring away from long-term NSAID and corticosteroid therapies of their sufferers. Continued scrutiny within the horse racing business round the usage of corticosteroids and efficiency enhancing medication (PED’s) sheds gentle on the necessity for a greater option to handle OA in equine athletes. The potential welfare-enhancing advantages and promise of decreasing the usage of corticosteroids & PED’s in racehorses is an additional advantage to this progressive product.
Arthramid®Vet is injected intra-articularly. A biocompatible hydrogel matrix types within the joint capsule, stabilizing the joint and synovium rising the elasticity of the joint. These mechanisms assist facilitate a discount in discomfort related to joint illness and reduces lameness by bettering joint perform. Arthramid®Vet is an inert substance, subsequently doesn’t obtain its supposed functions by way of metabolization or chemical motion. There isn’t any disruption of nerve perform.
Arthramid®Vet works inside broken joints by stimulating endogenous exercise of synoviocytes through tissue ingrowth into the hydrogel matrix. This implies will probably be helpful in all levels of osteoarthritis together with the earliest stage, generally often known as synovitis. Dr. Nancy Loving, in a March 2020 article about the usage of polyacrylamide hydrogels in horses, wrote “With power synovitis, synovial fluid inside the degraded synovial membrane recesses and inhibits tissue development and interferes with illness modification. Injected hydrogel lays throughout the synovial membrane and its absorption permits proliferation and differentiation of intimal cells and fibroblasts to thicken the membrane and produce regular synovial fluid inside the joint to counteract inflammatory mediators corresponding to cytokines.” [https://equimanagement.com/articles/polyacrylamide-hydrogel-for-intercarpal-osteoarthritis]
Main veterinarians skilled with Arthramid®Vet know the way helpful it may be. Dr Marc Koene – Founder and Companion on the internationally identified Tierklinik Lüsche GmbH Equine Hospital in Northern Germany acknowledged, “I used to be one of many first vets to make use of Arthramid®Vet worldwide and have now used Arthramid®Vet for over 10 years in our clinic. It has been a serious game-changer in the best way we deal with OA in our sufferers.”
Osteoarthritis accounts for as much as 60% of lameness in horses and is a debilitating, performance-limiting situation. Present therapies for OA in horses embrace injections of corticosteroids usually mixed with hyaluronic acid. Arthramid®Vet incorporates no lively pharmaceutical elements and the hydrogel materials contained in Arthramid®Vet’s patented components is hydrophilic, homogenous, biocompatible, viscoelastic, and is totally non-toxic. No allergic reactions have been reported thus far.
A not too long ago revealed double-blinded optimistic management examine in racing Thoroughbreds with carpal OA confirmed 83% of Arthramid®Vet 2.5% PAAG handled joints have been lame free at 6 weeks vs. 27% for Triamcinolone (corticosteroid) and 40% HA (hyaluronic acid) (p<0.05); revealed September 2021. [https://www.sciencedirect.com/science/article/pii/S073708062100410X?via=ihub]
Michaela M. Arcaro, COO of Contura Vet acknowledged, “We’re very excited to have a everlasting presence in the USA market. We consider our patented PAAG hydrogels symbolize a significant new different within the administration of osteoarthritis and urinary incontinence for horses and canine. Our robust presence within the OA and UI market worldwide makes us keenly conscious of the rising want for these merchandise within the veterinary market within the USA. Our merchandise present veterinary practitioners with a brand new instrument within the ever-present battle towards osteoarthritis and urinary incontinence; they’ll make a optimistic influence on the general welfare of the animals managed with them. This will even end in secondary optimistic impacts to the homeowners of those animals as they see enchancment of their beloved horses and canine. It’s actually a trifecta of positivity – veterinarians have a brand new instrument to raised handle debilitating circumstances of their sufferers, animals reap the well being and welfare advantages of receiving these new therapies and their homeowners discover reduction in bettering the standard of lifetime of their animals.”
Be taught extra about Contura Vet’s merchandise and place orders right here: www.conturavetus.com
About Contura Worldwide LTD and Contura Vet
Contura and Contura Vet carry collectively the mixed expertise of bioengineering and veterinary experience within the growth of merchandise for the therapy of osteoarthritis and urinary incontinence in people, horses, and canine. For greater than 20 years, now we have been creating the performance of our hydrogel merchandise throughout a number of therapeutic areas to be able to ship higher high quality of life to sufferers. Along with our patented know-how, we work with worldwide pharmaceutical and medical system producers which permits us to supply complete therapy choices. By working with the scientific neighborhood and utilizing our intensive experience, we search out new areas the place our distinctive hydrogel know-how provides important benefits over current applied sciences. Our hydrogel merchandise are developed and produced in our state-of-the-art GMP-approved manufacturing facility in Denmark. Our merchandise are the one veterinary polyacrylamides out there within the USA manufactured in an FDA authorized facility. We provide the secure selection for horses and canine.
